System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment [0.03%]
阿尔茨海默病诊断与治疗的医疗体系准备情况及患者诊疗路径
B Joy Snider,Alessandro Biffi,Sasha Bozeat et al.
B Joy Snider et al.
Promising therapeutic interventions that target the underlying pathophysiology are changing the landscape of Alzheimer's disease (AD) research. The AD care pathway must be transformed to meet the challenge of bringing these new therapies to...
BDNF Val66Met polymorphism moderates associations between physical activity and neurocognitive outcomes in older adults [0.03%]
脑源性神经营养因子多态性调节身体活动与老年人神经认知结果间的联系
Claire J Cadwallader,Anna M VandeBunte,D Luke Fischer et al.
Claire J Cadwallader et al.
Introduction: Increased brain-derived neurotrophic factor (BDNF) release through physical activity (PA) is thought to underlie protective effects of PA on brain aging. The BDNF Val66Met single-nucleotide polymorphism (rs6...
Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812 [0.03%]
阿尔茨海默病药物候选药物CT1812 II期临床试验中脑脊液药效学生物标志物和大脑活动分子相关性的鉴定
Valentina Di Caro,Eunah Cho,Hilary A North et al.
Valentina Di Caro et al.
Introduction: CT1812 (zervimesine) is an orally dosed modulator of the sigma-2 receptor (S2R) currently in clinical development for the treatment of Alzheimer's disease (AD). CT1812 has been shown in preclinical and early...
Alzheimer's disease genetic risk: Top African American risk allele frequencies and genetic architecture among Mexican-, African-, and non-Hispanic White Americans [0.03%]
阿尔茨海默病的遗传风险：非洲裔美国人风险等位基因频率及墨西哥人、非西班牙裔白人和非洲裔美国人的遗传结构
Mohammad Housini,Zhengyang Zhou,Lubnaa Abdullah et al.
Mohammad Housini et al.
Introduction: Alzheimer's disease (AD) continues to be the sixth leading cause of death in the United States. Significant efforts are spent researching etiology and potential management strategies. Although minorities fac...
The promotion of physical activity for use in Alzheimer's disease prevention trials in adults with Down syndrome: Results from a 12-month randomized trial [0.03%]
促进唐氏综合征成人阿尔茨海默病预防试验中的体育活动：一项为期12个月的随机对照试验的结果
Lauren T Ptomey,Brian C Helsel,Richard A Washburn et al.
Lauren T Ptomey et al.
Introduction: Alzheimer's disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Participation in moderate-to-vigorous physical activity (MVPA) may prevent or delay the onset of AD. Therefore, ...
Programmatic research outcomes used to establish the evidence-base of dementia caregiving support programs: An analysis of Best Programs for Caregiving [0.03%]
用于建立痴呆症护理支持项目证据基础的研究成果型产出的程序化研究：最佳护理项目的分析
Morgan J Minyo,Sara M Powers,David M Bass et al.
Morgan J Minyo et al.
Introduction: A substantial number of evidence-based dementia caregiving support programs positively impact family and friend caregivers. Researchers and service organizations have successfully translated and delivered a ...
Translation with ongoing adaptation and improvement (ToAI) framework: A community-informed, structured, iterative approach to culturally adapting cognitive assessment tools [0.03%]
基于社区的结构化迭代文化适应认知评估工具的方法框架（为了不断适应和改进）
Quyen Q Tiet,Sarah Tomaszewski Farias,Duyen Tran et al.
Quyen Q Tiet et al.
Introduction: Alzheimer's disease (AD) and related dementias (ADRD) are increasing globally, including in the United States, but the fast-growing Vietnamese American population remains understudied, with a significant lac...
Time saved in activities of daily living and whole-brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease [0.03%]
每日生活活动时间的节省与全脑体积的关系：γ振荡治疗轻度或中度阿尔茨海默病参与者的随机可行性试验的事后分析
Ralph Kern,Benjamin Haaland,Jessie Nicodemus-Johnson et al.
Ralph Kern et al.
Introduction: Gamma oscillations in the brain are necessary for normal cognitive function, sensory processing, and memory consolidation, and are reduced in Alzheimer's disease (AD). In a 6 month, randomized, feasibility t...
The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment [0.03%]
LATTICE研究：小剂量锂盐治疗轻度认知障碍以延缓认知衰退的可行性随机对照试验方案
Ariel G Gildengers,Tamer S Ibrahim,Xuemei Zeng et al.
Ariel G Gildengers et al.
Introduction: Interest has grown in lithium's neuroprotective properties in neurodegenerative illnesses. We discuss the design, rationale, and implementation of a pilot feasibility, double-blind, randomized placebo-contro...
Estimating the optimal cutoff for the IGT-AD Distress subscale adapted for amyloid PET results disclosure [0.03%]
基于淀粉样PET结果的IGT-AD困扰亚量表最优临界值估计
Dianxu Ren,Kim Jeong Eun,Joshua D Grill et al.
Dianxu Ren et al.
Introduction: Research on diagnostic and biomarker disclosure has significantly increased, particularly in the field of Alzheimer's disease (AD). The psychological impact of learning amyloid positron emission tomography (...